Pretreatment of H4 (rat hepatoma) cells for 48 hr with low nontoxic doses of alkylating agents [methyl methanesulfonate (MMS), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), and N-methyl-N-nitrosoureal renders the cells more resistant to the toxic effect of these compounds. Cross When Escherichia coli cells are continuously exposed to nontoxic levels of a simple alkylating agent, such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or N-methyl-N-nitrosourea (MNU), an adaptative DNA repair pathway is induced. It protects the bacteria against the killing and mutagenic effects of high toxic doses of alkylating agents (1-3). This adaptive response is also observed in Micrococcus luteus (4).
When Escherichia coli cells are continuously exposed to nontoxic levels of a simple alkylating agent, such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or N-methyl-N-nitrosourea (MNU), an adaptative DNA repair pathway is induced. It protects the bacteria against the killing and mutagenic effects of high toxic doses of alkylating agents (1) (2) (3) . This adaptive response is also observed in Micrococcus luteus (4) .
In Escherichia coli, different processes are implicated in the adaptive response. Adaptation to killing by alkylating agents is attributed to the induction of high levels of a DNA glycosylase, coded by the alk gene (5) , which excises 3-methyladenine, 3-methylguanine (6), and 7-methylguanine (6, 7) . Resistance to mutagenesis has been attributed to the induction of high levels of an 06-alkylguanine methyltransferase (8) (9) (10) .
Evidence for an adaptive response in mammals comes from the experiments of Montesano et al. (ref. 11 ; reviewed in ref. 12) , showing that the livers of rats continuously exposed to low levels of dimethylnitrosamine and then challenged with high doses of dimethylnitrosamine, accumulate 7-methylguanine but not 06-methylguanine (O6MeGua) in their DNA. Of the several animal species used for such studies, only the rat shows an increase in methyltransferase.
In vitro, it has been shown that chronic treatment of Chinese hamster ovary (CHO) cells with nontoxic doses of MNNG renders the cells resistant to both killing and formation of sister chromatid exchanges upon further treatment with high toxic levels of MNNG or MNU (13) . A single incubation of V79 Chinese hamster cells with a subtoxic dose of MNNG or MNU also modifies the cell sensitivity towards these agents (14) .
In mammalian cells, 7-alkylguanine, 3-alkyladenine, and 3-alkylguanine are enzymatically excised through a DNA glycosylase pathway that creates an apurinic site (15) (16) (17) , whereas O6MeGua is repaired by a transalkylase (18) . Therefore, mammalian cells contain the potential proteins that could mimic the situation observed in adapted E. coli.
The aim of our work was to determine whether mammalian cells could be adapted for killing and mutagenesis by repeated treatment with low nontoxic concentrations of alkylating agents and whether these effects could be related to the type of damage induced by the drugs. We used simple alkylating agents [methyl methanesulfonate (MMS) and MNNG] that differ in their mutagenicity and give different spectra of methylated bases (19) (20) (21) . The results show that adaptation to killing and mutagenesis are two independent processes and that adaptation to mutagenesis, in contrast to carcinogenesis, can be correlated with the amount of O6MeGua produced in cellular DNA during the adaptive treatment.
MATERIALS AND METHODS
Chemical Reagents. Dulbecco's medium and sera were GIBCO products. MNNG and MNU were purchased from Sigma. MMS was obtained from Aldrich. MNNG and MNU were dissolved in spectrophotometric grade acetone. Aliquots were placed in test tubes in the dark, and the acetone was evaporated under a stream of N2 gas. The tubes were kept at -20°C. Prior to use, the tubes were thawed, and the mutagen was dissolved (1 mg/ml) in 0.1 M NaOAc (pH 4.0) and then diluted in Earle's balanced salt solution (50 ,ug/ml). Cell Culture. H4 cells, which are epithelial cells derived from a rat hepatoma (22) were obtained as a gift from J. B. Little (Harvard University). They were grown in Dulbecco's medium supplemented with 5% fetal calf serum, 5% horse serum, penicillin (50 units/ml), and streptomycin (50 ,ug/ml) in humidified 5% C02/95% air. The doubling time was about 14 hr. Cultures were periodically checked and found free of mycoplasma contamination. When H4 cells are cultured with daily medium changes, they reach a stable density-inhibited plateau in growth (22 (22) . The DNA was recovered, dialyzed against potassium phosphate (1 mM, pH 7.6), and then hydrolyzed to purine bases and oligodeoxyribonucleotides as described by Frei et al. (24) . DNA hydrolysates were analyzed by using Waters HPLC equipment (25) as described by Frei et al. (24) . The amount of DNA P was calculated as described by Medcalf and Lawley (26) , and the amount of alkylated bases was determined by liquid scinitillation counting.
Measurements of total acid-soluble thiols was as follows.
Six hours after the end of the adaptive treatment, pretreated and control cells (3 x 107 cells) were washed, harvested by trypsinization, centrifuged, and resuspended in 1 ml of 5% trichloroacetic acid. After centrifugation, aliquots of the supernatant were added to 1.4 ml of dithiobis(2-nitrobenzoic acid) (200 mg/ml in 0.2 M sodium phosphate buffer, pH 7.6) as described by Ellman (27 (Fig. 3A) . Because this low mutation frequency in adapted cells could be due to a modification of the expression time in the MNNG, ,uM pretreated cultures, the number of mutants was determined at different times after the incubation with each challenge dose of mutagen (1-9 days). In both control and pretreated cells, the optimal expression time was found to be 5 days. Therefore, this hypothesis cannot account for the decrease of mutation frequency in adapted cells. When the cells were pretreated with MMS and then challenged with the same compound, the mutation frequency was not significantly modified under our experimental conditions (Fig. 3B) . The same result was obtained in a cross-experiment, with cells pretreated with low MMS doses and then challenged with MNNG ( Fig. 3C ): adapted and nonadapted cells produced an equal number of 6SGua-resistant mutants. Therefore, a pretreatment with MMS enhances the survival of cells challenged with either MMS or MNNG as shown in Fig. 2 but is unable to modify the mutation frequency induced by these two compounds.
Kinetics of 06MeGua Removal. As mutagenesis has been related in a number of experiments to the persistence of O6MeGua in cellular DNA, experiments were designed to measure the mutation frequency in control and adapted cells as a function of the kinetics of O6MeGua removal. In order to avoid dilution of bases by DNA synthesis, an appropriate number of cells (5 x 106 cells in 75-cm2 flasks) was seeded that allowed the cultures to reach confluency at the end of the pretreatment period. Under these conditions, the adaptive response was similar to that described above. Control cells and cells pretreated with either MMS or MNNG were incubated for 30 min with [14C]MNNG (0.27 mM). The cells were washed and harvested after 0, 2, 3.5, or 24 hr of subsequent incubation. The cellular DNA was then purified and hydrolyzed, and the O6MeGua was separated by HPLC and determined. Fig. 4 shows the kinetics of O6MeGua removal. The initial amount of induced O6MeGua had the same value in control cells and in cells with and without adaptation with MMS or MNNG. In control and MMS-pretreated cells, O6MeGua was removed with the same slow biphasic kinetics: during the early postincubation times, about 1.7 ,umol of 06MeGua per mol of DNA P was removed per hr, whereas later the rate of removal decreased to 0.23 ,mol/hr. In MNNG-pretreated cells, O6MeGua was also removed with two-compo- Proc. NatL Acad ScL USA 81 (1984) nent kinetics. However, this lesion was removed with a much higher efficiency than in control or in MMS-adapted cells. In this case, the rate of removal was about 5 ,tmol of O6MeGua per mol of DNA P per hr, and no O6MeGua was detectable 24 hr after the challenging treatment. The kinetics of N7-methylguanine (N7MeGua) removal was determined also and found to be at variance with that observed for O6MeGua because N7MeGua was removed at the same rate in control and in MMS-or MNNG-pretreated cells, with a half-life of -25 hr (data not shown).
Comparative The concentrations of MMS (25 ,uM) and MNNG (0.27 ,uM) used during the pretreatment did not allow accurate determination of the amounts of O6MeGua by analysis of cellular DNA. By assuming that these amounts are proportional to the concentration of the alkylating agent, they can be extrapolated from the data reported in Table 2 : in order to obtain with MMS the same amount of O6MeGua as that formed with 0.27 ,uM MNNG in the cellular DNA, one needs 158 ,M MMS (0.27 x 588). However, as shown in Fig. 1 , this MMS concentration is much too toxic and does not induce adaptive response in the cells.
DISCUSSION
When H4 cells are exposed to low (nontoxic) concentrations of alkylating agents, they become less sensitive to the toxic effect of these compounds. We observed this phenomenon with MMS, MNNG, and MNU, and crossreactivity of the adaptive response towards cell survival was also observed with these drugs.
It has been shown that the cell sensitivity towards MNNG could fluctuate throughout the cell cycle (28) and that nonproliferating cells were more sensitive to MMS than exponentially growing cells, the increased sensitivity arising from the loss of the shoulder that is a characteristic of the survival curves obtained with this drug (29) . However, the survival enhancement observed in adapted cells cannot be related to such modifications, as the cell cycle was not modified during the pretreatment period under our experimental conditions. It also has been shown that MNNG is activated by thiol groups (30) . Therefore, a modification of the intracellular thiol level during the pretreatment could explain the enhanced cell survival observed with this compound. This hypothesis was ruled out, as the total thiol level was not modified in adapted cells. It also was determined that the alkylation of cellular DNA by MNNG was not modified after the pretreatment period. An adaptive response to the killing effect of alkylating agents (MNNG and MNU) has been reported in CHO cells (13) and in V79 cells (14) with different adaptive protocols. Therefore, adaptation to the toxic effect of alkylating agents occurs in different cell lines, but the survival enhancement varies among the cell lines studied. The adaptive response in mammalian cells is of lesser magnitude than that reported to be in bacteria, although it should be recalled that in E. coli, adaptation is less effective in the K12 strain than in B/r (31).
However, controversy exists about the adaptive response of mammalian cells to mutagenicity. After 48 hr of chronic pretreatment with MNNG, the mutation frequency in CHO cells is not modified when the cells are challenged with the same agent (32) . Pretreatment with MNU increases the cell survival but does not modify the mutagenicity of V79 cells (33) . Opposite results were obtained by Kaina et al. (14) , who showed that a single exposure of V79 cells to a subtoxic dose of MNU or MNNG renders the cells resistant to the mutagenic effect of these agents given 6 hr later.
Under our experimental conditions, pretreatment with MNNG renders the cells resistant to the mutagenic effects of high concentrations of this compound. However, pretreatment with MMS is unable to induce mutagenic resistance in cells challenged with either MMS or MNNG. The crossreactivity observed for cell survival does not exist for mutagenicity. This suggests that adaptive responses to killing and mutagenesis are at least partially independent processes.
Among the different lesions induced in cellular DNA by alkylating agents, at least six, including 06-alkylguanine are mutagenic (20) . In the case of 06-alkylguanine, the lesion is repaired by an alkyl transferase (18, 34) , which is present in limited amounts in the cells (9) . A possible pathway leading to mutation resistance could be a more efficient O6MeGua removal in adapted cells. Although mammalian cells differ in their ability to repair O6MeGua (35, 36) , it has been shown that in vivo rat liver cells were able to remove this lesion (37) . Under our experimental conditions, cultured rat hepatoma cells remove O6MeGua, and the results show a correlation between the efficiency of 06MeGua removal and the decrease of mutagenicity in MNNG-pretreated cells. Furthermore, the MMS-pretreatment, which is not effective to adapt to mutagenesis, does not modify the disappearance of O6MeGua in H4 cells.
As reported for other cell lines (36) If we assume that this ratio is also true when the cells are treated with low concentrations of alkylating agents (40) , this means that the MMS concentration of 25 tsM, which adapts the cell for survival but not for mutagenesis, induces much less 06MeGua than does the MNNG dose (0.27 gM) used during the pretreatment. However, higher MMS concentrations cannot be used during the pretreatment because of the toxicity of this compound. Therefore, if 06MeGua is involved in inducing killing resistance, it is probably not the only damage involved in this process. However, O6MeGua appears to be essential to induce mutagenesis resistance, and adaptation to mutagenesis is probably related to the amount of 06MeGua produced during the adaptive period, although the role of other alkylated bases cannot be excluded.
Variations in the amount of 06MeGua induced in the pretreated cells are a probable explanation for the failure of other investigators to find adaptation to mutagenesis. Adaptive treatments might produce enough damage to induce killing resistance but not enough 06MeGua to render the cells resistant to mutagenesis. It should be recalled that the extent of alkylation varies with the nature of the drug (19) and the drug concentration (40) used during the pretreatment. In the case of MNNG, the intracellular thiol concentration is also critical in the generation of the methylation species (30) .
It should be pointed out that most of the drugs used during cancer therapy are or are metabolized to alkylating agents. The appearance of an adaptive response during these treatments, which are pursued for long periods, cannot be excluded. Therefore, according to the drug and its methylating properties, adaptation could occur for survival or for mutagenesis, thus modifying the efficiency of the treatment or the appearance of iatrogenic diseases.
